Catalyst Pharmaceuticals (CPRX) EBITDA Margin (2018 - 2026)
Catalyst Pharmaceuticals posted quarterly EBITDA Margin of 42.67% for Q1 2026, up 261.0% year-on-year from 11.82% in Q1 2025, and up 23.57% on a QoQ basis from 34.53% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 9 years of EBITDA Margin data on file, last reported at 42.67% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 261.0% year-over-year to 42.67%; the trailing twelve-month figure through Mar 2026 stood at 37.08% (up 17.0% YoY), and the FY2025 full-year result was 36.38%, up 304.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 42.67%, up from 34.53% in the prior quarter.
- Across five years, EBITDA Margin topped out at 42.67% in Q1 2026 and bottomed at 29.96% in Q3 2023.
- The 5-year median for EBITDA Margin is 35.55% (2025), against an average of 32.13%.
- The widest annual swing landed in 2023, when EBITDA Margin tumbled 6998 bps; it then surged 6406 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 41.91% in 2022, then retreated by 25 bps to 31.51% in 2023, then advanced by 25 bps to 39.49% in 2024, then retreated by 13 bps to 34.53% in 2025, then climbed by 24 bps to 42.67% in 2026.
- The last three EBITDA Margin figures came in at 42.67% (Q1 2026), 34.53% (Q4 2025), and 35.55% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 42.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.67% |
| Dec 31, 2025 | 34.53% |
| Sep 30, 2025 | 35.55% |
| Jun 30, 2025 | 35.59% |
| Mar 31, 2025 | 40.06% |
| Dec 31, 2024 | 39.49% |
| Sep 30, 2024 | 34.10% |
| Jun 30, 2024 | 33.24% |
| Mar 31, 2024 | 23.61% |
| Dec 31, 2023 | 31.51% |
| Sep 30, 2023 | -29.96% |
| Jun 30, 2023 | 37.93% |
| Mar 31, 2023 | 34.62% |
| Dec 31, 2022 | 41.91% |
| Sep 30, 2022 | 40.02% |
| Jun 30, 2022 | 41.31% |
| Mar 31, 2022 | 30.02% |
| Dec 31, 2021 | 24.08% |
| Sep 30, 2021 | 28.66% |
| Jun 30, 2021 | 33.52% |
| Mar 31, 2021 | 25.12% |
| Dec 31, 2020 | 37.00% |
| Sep 30, 2020 | 147.82% |
| Jun 30, 2020 | 32.75% |
| Mar 31, 2020 | 36.04% |
| Dec 31, 2019 | 26.29% |
| Sep 30, 2019 | 44.11% |
| Jun 30, 2019 | 38.10% |
| Mar 31, 2019 | -5.07% |
| Dec 31, 2018 | -2,894.78% |